In the present study, 43 key targets of DMSCO were identified for AD treatment and the top 10 targets were TP53, MAPK1, AKT1, VEGFA, INS, IL6, STAT3, PIK3CA, MAPK8 and MAPK3. Here, VEGFA is linked to Alzheimer disease.